Metastatic Colorectal Cancers Recruiting Phase Trials for Bevacizumab (DB00112)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)RecruitingNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02256800Prospective Analysis of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Combined With FOLFIRI as the First-line SettingTreatment
NCT01860144An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer
NCT01912443Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer
NCT02842294Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer